Clinical Trials · NCT05183802

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

Name: An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Approved For MarketingN/ASetmelanotide

Phase: N/A
Recruitment status: Approved For Marketing
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 0
Start date: Not specified
Locations: See registry
Primary endpoint: Study in Bardet-Biedl Syndrome (BBS)

View Setmelanotide compound reference